These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 25990354

  • 1. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 2. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R.
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [Abstract] [Full Text] [Related]

  • 4. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [Abstract] [Full Text] [Related]

  • 5. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 6. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
    Naylor KE, McCloskey EV, Jacques RM, Peel NFA, Paggiosi MA, Gossiel F, Walsh JS, Eastell R.
    Osteoporos Int; 2019 Apr; 30(4):917-922. PubMed ID: 30613868
    [Abstract] [Full Text] [Related]

  • 7. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P.
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [Abstract] [Full Text] [Related]

  • 8. A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
    Yates J.
    Osteoporos Int; 2013 Jan; 24(1):253-62. PubMed ID: 23100120
    [Abstract] [Full Text] [Related]

  • 9. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
    Ebina K, Noguchi T, Hirao M, Hashimoto J, Kaneshiro S, Yukioka M, Yoshikawa H.
    Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
    Bae SJ, Kim BJ, Lim KH, Lee SH, Kim HK, Kim GS, Koh JM.
    J Bone Miner Metab; 2012 Sep; 30(5):588-95. PubMed ID: 22610063
    [Abstract] [Full Text] [Related]

  • 11. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
    van den Berg P, van Haard PMM, van der Veer E, Geusens PP, van den Bergh JP, Schweitzer DH.
    Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 13. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, Xia WB, Meng XW.
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [Abstract] [Full Text] [Related]

  • 14. The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study.
    Gossiel F, Paggiosi MA, Naylor KE, McCloskey EV, Walsh J, Peel N, Eastell R.
    Bone; 2020 Feb; 131():115158. PubMed ID: 31740343
    [Abstract] [Full Text] [Related]

  • 15. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 16. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K, Harigane K, Kusayama Y, Tezuka T, Choe H, Inaba Y, Saito T.
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [Abstract] [Full Text] [Related]

  • 17. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI.
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
    Kučukalić-Selimović E, Valjevac A, Hadžović-Džuvo A, Skopljak-Beganović A, Alimanovic-Alagić R, Brković A.
    Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
    [Abstract] [Full Text] [Related]

  • 19. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
    Frost ML, Siddique M, Blake GM, Moore AE, Marsden PK, Schleyer PJ, Eastell R, Fogelman I.
    Osteoporos Int; 2012 Aug; 23(8):2107-16. PubMed ID: 21983795
    [Abstract] [Full Text] [Related]

  • 20. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E.
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.